Landos Biopharma Inc
LABP
Get informed when a big investor buys or sells
+ FollowMarket Cap$71.68M
Close$
$5.98
73.9% downside
Current Fair Value
73.9% downsideOvervalued by 73.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $71.68 Million |
|---|---|
| Enterprise Value | $42.62 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.5 |
| Beta | 0.14 |
| Outstanding Shares | 6,207,637 |
Return
| Return on Equity | -107.10% |
|---|---|
| Return on Assets | -82.95% |
| Return on Invested Capital | -108.83% |
Valuation & Multiples
| P/E Ratio | -6.56 |
|---|---|
| PEG | -11.08 |
| Price to Sales | - |
| Price to Book Ratio | 7.64 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.69 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Landos Biopharma Inc
33 employeesLandos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases that are the first to target new mechanisms of action, including the LANCL...